Breadcrumb

MEDIA_REFRESH_DATA_PRESS_RELEASE

Media

U.S. News Room

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

Thu May 22 00:00:00 GMT-05:00 2025 NEW
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO Download
Mon May 19 00:00:00 GMT-05:00 2025 NEW
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma Download
Wed May 07 00:00:00 GMT-05:00 2025 NEW
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial Download
Mon Apr 21 00:00:00 GMT-05:00 2025
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer Download
Mon Mar 31 00:00:00 GMT-05:00 2025
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer Download
Mon Mar 03 00:00:00 GMT-05:00 2025
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial Download
Thu Jan 30 00:00:00 GMT-05:00 2025
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer Download
Thu Jan 30 00:00:00 GMT-05:00 2025
TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse Download
Mon Jan 27 00:00:00 GMT-05:00 2025
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies Download
Tue Jan 21 00:00:00 GMT-05:00 2025
Daiichi Sankyo Establishes “Smart” Research Laboratory in San Diego to Expedite Drug Discovery Download
Showing 1 - 10 of 187 results.